Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38:2677–2694. doi:10.1200/JCO.20.00866
   PubMed Web of Science ®Google Scholar
• Eyck BM, van Lanschot JJB, Hulshof M, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995–2004. doi:10.1200/JCO.20.03614
   PubMed Web of Science ®Google Scholar
• Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156:721–729. doi:10.1001/jamasurg.2021.2373
   PubMed Web of Science ®Google Scholar
• de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38:326–333. doi:10.1016/j.ccell.2020.07.004
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Zhao Q, Yu J, Meng X. A good start of immunotherapy in esophageal cancer. Cancer Med. 2019;8:4519–4526. doi:10.1002/cam4.2336
   PubMed Web of Science ®Google Scholar
• Kojima T, Doi T. Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep. 2017;19:33. doi:10.1007/s11912-017-0590-9
   PubMed Web of Science ®Google Scholar
• Salem ME, Puccini A, Xiu J, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist. 2018;23:1319–1327. doi:10.1634/theoncologist.2018-0143
   PubMed Web of Science ®Google Scholar
• Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17:38–44. doi:10.1016/j.semradonc.2006.09.007
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant Pd-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, Phase II Study (TD-NICE). Int J Surg. 2022;103:106680. doi:10.1016/j.ijsu.2022.106680
   PubMed Web of Science ®Google Scholar
• Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2020;26:4542–4550. doi:10.1158/1078-0432.CCR-19-3561
   PubMed Web of Science ®Google Scholar
• Shang X, Zhao G, Liang F, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (Stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, Phase-II Trial (Keystone-001). Ann Transl Med. 2022;10:229. doi:10.21037/atm-22-513
   PubMed Web of Science ®Google Scholar
• Yang P, Zhou X, Yang X, et al. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. World J Surg Oncol. 2021;19:333. doi:10.1186/s12957-021-02446-5
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:855–883. doi:10.6004/jnccn.2019.0033
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50:12–20. doi:10.1007/s00595-019-01878-7
   PubMed Web of Science ®Google Scholar
• Wang LH, Huang J, Han YT. The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Esophageal Cancer. China: People’s Health Press. 2022
   Google Scholar
• Wong IYH, Lam KO, Zhang RQ, et al. Neoadjuvant chemoradiotherapy using cisplatin and 5-Fluorouracil (PF) versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): a Propensity Score-Matched Study. Ann Surg. 2020;272:779–785. doi:10.1097/SLA.0000000000004329
   PubMed Web of Science ®Google Scholar
• Ai D, Ye J, Wei S, et al. Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: a Randomized Clinical Trial. JAMA Netw Open. 2022;5:e220120. doi:10.1001/jamanetworkopen.2022.0120
   PubMed Web of Science ®Google Scholar
• Wan T, Zhang XF, Liang C, et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies. Ann Surg Oncol. 2019;26:1412–1420. doi:10.1245/s10434-018-07147-0
   PubMed Web of Science ®Google Scholar
• Gopaldas RR, Bhamidipati CM, Dao TK, et al. Impact of surgeon demographics and technique on outcomes after esophageal resections: a Nationwide study. Ann Thorac Surg. 2013;95:1064–1069. doi:10.1016/j.athoracsur.2012.10.038
   PubMed Web of Science ®Google Scholar
• Pol J, Vacchelli E, Aranda F, et al. Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4:e1008866. doi:10.1080/2162402X.2015.1008866
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436–443. doi:10.1158/2326-6066.CIR-15-0064
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61–69. doi:10.1007/s10555-011-9273-4
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–221. doi:10.1016/j.canlet.2018.01.050
   PubMed Web of Science ®Google Scholar
• Shen D, Chen Q, Wu J, et al. The safety and efficacy of neoadjuvant Pd-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12:1–10. doi:10.21037/jgo-20-599
   PubMed Web of Science ®Google Scholar
• Wu Z, Zheng Q, Chen H, et al. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 2021;13:3518–3528. doi:10.21037/jtd-21-340
   PubMed Web of Science ®Google Scholar
• Liu J, Yang Y, Liu Z, et al. Multicenter, Single-Arm, Phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10:e004291. doi:10.1136/jitc-2021-004291
   PubMed Web of Science ®Google Scholar
• Yang W, Xing X, Yeung SJ, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10:e003497. doi:10.1136/jitc-2021-003497
   PubMed Web of Science ®Google Scholar
• Sihag S, Ku GY, Tan KS, et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 2021;161:836–843.e1. doi:10.1016/j.jtcvs.2020.11.106
   PubMedGoogle Scholar
• Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021;144:232–241. doi:10.1016/j.ejca.2020.11.039
   PubMed Web of Science ®Google Scholar
• van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a Single-Arm Phase II Feasibility Trial (PERFECT). Clin Cancer Res. 2021;27:3351–3359. doi:10.1158/1078-0432.CCR-20-4443
   PubMed Web of Science ®Google Scholar